• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在生长抑素受体SPECT/CT检查中,99mTc-HYNIC-TOC摄取增加可模拟胰腺钩突部的恶性病变。

99mTc-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT/CT.

作者信息

Yamaga Lilian Yuri Itaya, Neto Guilherme Campos Carvalho, da Cunha Marcelo Livorsi, Osawa Akemi, Oliveira Julio Cesar Silveira, Fonseca Ricardo Quartim, Nogueira Solange Amorim, Wagner Jairo, Funari Marcelo Gusmão

机构信息

Imaging Department, Albert Einstein Hospital, Av. Albert Einstein, 627, São Paulo, CEP: 05651-090, Brazil.

出版信息

Radiol Med. 2016 Mar;121(3):225-8. doi: 10.1007/s11547-015-0593-2. Epub 2015 Nov 12.

DOI:10.1007/s11547-015-0593-2
PMID:26558391
Abstract

OBJECTIVE

The aim of this study was to assess the occurrence and frequency of increased physiologic uptake of 99mTc-HYNIC-TOC by the uncinate process of the pancreas in SPECT/CT images.

METHODS

Forty-six scans of 41 patients were evaluated retrospectively. The uptake of 99mTc-HYNIC-TOC was considered to be physiologic in patients with normal findings at dedicated abdominal CT or MR and lack of neoplastic lesions in clinical follow-ups. The intensity of uncinate process uptake was compared to the uptake of the normal liver.

RESULTS

Focal uptake was attributed to the presence of pancreatic NET in 5 patients. Among the 36 patients without any evidence of malignancy in CT, MR and follow-up, 7 (19.4 %) showed increased uptake in the uncinate process. The intensity of uptake was lesser in 3 (8.3 %), similar in 3 and greater than the normal liver in 1 (2.8 %) case.

CONCLUSION

Increased 99mTc-HYNIC-TOC uptake occurred in 19.4 % of those subjects without any evidence of neuroendocrine tumor in the uncinate process.

摘要

目的

本研究旨在评估在SPECT/CT图像中胰腺钩突对99mTc-HYNIC-TOC生理性摄取增加的发生率和频率。

方法

对41例患者的46次扫描进行回顾性评估。在专门的腹部CT或MR检查结果正常且临床随访中无肿瘤病变的患者中,99mTc-HYNIC-TOC的摄取被认为是生理性的。将钩突摄取的强度与正常肝脏的摄取进行比较。

结果

5例患者的局灶性摄取归因于胰腺神经内分泌肿瘤。在36例CT、MR和随访中无任何恶性证据的患者中,7例(19.4%)钩突摄取增加。摄取强度在3例(8.3%)中较低,3例相似,1例(2.8%)大于正常肝脏。

结论

在钩突无任何神经内分泌肿瘤证据的受试者中,19.4%出现99mTc-HYNIC-TOC摄取增加。

相似文献

1
99mTc-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT/CT.在生长抑素受体SPECT/CT检查中,99mTc-HYNIC-TOC摄取增加可模拟胰腺钩突部的恶性病变。
Radiol Med. 2016 Mar;121(3):225-8. doi: 10.1007/s11547-015-0593-2. Epub 2015 Nov 12.
2
Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy.99mTc-HYNIC-TOC闪烁扫描术中胰腺生长抑素受体的生理表达
Clin Transl Oncol. 2017 Jul;19(7):915-920. doi: 10.1007/s12094-017-1616-3. Epub 2017 Jan 31.
3
Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.PET/CT 68Ga生长抑素受体显像对既往诊断为99mTc-EDDA/HYNIC-TOC SPECT的患者后续治疗的影响。
Nucl Med Rev Cent East Eur. 2016;19(2):88-92. doi: 10.5603/NMR.2016.0018.
4
Quantitative analysis of standardized uptake values (SUV) of metastatic bone lesions in scintigraphy with [99mTc]Tc-EDDA/HYNIC-Tyr3-octreotide in patients with neuroendocrine tumours.用[99mTc]Tc-EDDA/HYNIC-Tyr3-octreotide 闪烁显像测定神经内分泌肿瘤患者转移性骨病变的标准化摄取值(SUV)的定量分析。
Nucl Med Rev Cent East Eur. 2024;27(0):31-35. doi: 10.5603/nmr.99794.
5
Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.使用新型99mTc-三羟甲基氨基甲烷-HYNIC-D-苯丙氨酸1-酪氨酸3-奥曲肽检测生长抑素受体阳性肿瘤:患者的初步结果及与111In-DTPA-D-苯丙氨酸1-奥曲肽的比较
Eur J Nucl Med. 2000 Jun;27(6):628-37. doi: 10.1007/s002590050556.
6
Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.99mTc-HYNIC-Tyr3-octreotide 用于神经内分泌肿瘤的患者特异性辐射剂量测定。
J Nucl Med. 2011 Sep;52(9):1474-81. doi: 10.2967/jnumed.111.088203. Epub 2011 Jul 27.
7
Characterisation of 99mTc EDDA/HYNIC-TOC (Tektrotyd) physiological and neuroendocrine tumour uptake using SPECT/CT standardised uptake values: initial experience.使用 SPECT/CT 标准化摄取值对 99mTc-EDDA/HYNIC-TOC(替曲膦)的生理学和神经内分泌肿瘤摄取进行特征描述:初步经验。
Nucl Med Commun. 2021 Aug 1;42(8):935-939. doi: 10.1097/MNM.0000000000001416.
8
68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.68Ga-DOTA-TOC 在神经内分泌肿瘤和正常组织中的摄取:PET/CT 中生理性摄取与病理性过程的鉴别。
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):514-23. doi: 10.1007/s00259-012-2309-3. Epub 2013 Jan 5.
9
Normal uptake of 68Ga-DOTA-TOC by the pancreas uncinate process mimicking malignancy at somatostatin receptor PET.胰腺钩突部位对 68Ga-DOTA-TOC 的正常摄取,类似于生长抑素受体 PET 扫描中的恶性肿瘤表现。
Clin Nucl Med. 2012 Apr;37(4):362-5. doi: 10.1097/RLU.0b013e3182485110.
10
Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?[99mTc/EDDA/HYNIC0]奥曲肽衍生物与[111In-DOTA0,Tyr3,Thr8]奥曲肽和[111In-DTPA0]奥曲肽的比较评估:肿瘤或胰腺摄取与内化率相关吗?
J Nucl Med. 2005 Sep;46(9):1561-9.

引用本文的文献

1
Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms.生长抑素与生长抑素受体:从信号传导到神经内分泌肿瘤的临床应用
Biomedicines. 2021 Dec 1;9(12):1810. doi: 10.3390/biomedicines9121810.
2
Tc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases).Tc-EDDA/HYNIC-TOC 是肺部神经内分泌肿瘤(以及其他恶性和良性肺部疾病)的新机遇。
Curr Radiopharm. 2020;13(3):166-176. doi: 10.2174/1874471013666191230143610.
3
Prevalence and quantitative analysis of indium-111 pentetreotide (Octreoscan) uptake in the pancreatic head on SPECT/CT imaging: establishing a region of interest-based pathological uptake threshold.

本文引用的文献

1
68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.68Ga-DOTA-TOC 在神经内分泌肿瘤和正常组织中的摄取:PET/CT 中生理性摄取与病理性过程的鉴别。
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):514-23. doi: 10.1007/s00259-012-2309-3. Epub 2013 Jan 5.
2
Semiquantitative analysis and characterization of physiological biodistribution of (68)Ga-DOTA-TATE PET/CT.半定量分析及(68)Ga-DOTA-TATE PET/CT 生理生物分布特征。
Clin Nucl Med. 2012 Nov;37(11):1052-7. doi: 10.1097/RLU.0b013e31825b2555.
3
Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT.
SPECT/CT成像中胰腺头部铟-111喷替肽(奥曲肽扫描)摄取的患病率及定量分析:基于感兴趣区确定病理摄取阈值
Nucl Med Commun. 2019 Jul;40(7):727-733. doi: 10.1097/MNM.0000000000001022.
4
Tc-Hynic-TOC imaging in the diagnostic of neuroendocrine tumors.锝[99mTc]标记的依克昔泮-奥曲肽显像在神经内分泌肿瘤诊断中的应用
World J Nucl Med. 2018 Jul-Sep;17(3):151-156. doi: 10.4103/wjnm.WJNM_41_17.
5
Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy.99mTc-HYNIC-TOC闪烁扫描术中胰腺生长抑素受体的生理表达
Clin Transl Oncol. 2017 Jul;19(7):915-920. doi: 10.1007/s12094-017-1616-3. Epub 2017 Jan 31.
在一系列连续 PET/CT 研究的胰外神经内分泌肿瘤患者中,胰腺头部的 68Ga-DOTANOC 摄取增加的发生率。
J Nucl Med. 2011 Jun;52(6):886-90. doi: 10.2967/jnumed.111.088328. Epub 2011 May 13.
4
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.68Ga-DOTANOC PET/CT 对神经内分泌肿瘤患者的临床影响。
J Nucl Med. 2010 May;51(5):669-73. doi: 10.2967/jnumed.109.071712. Epub 2010 Apr 15.
5
Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors.神经内分泌肿瘤 111In 五肽 SPECT/CT 融合显像的增值价值。
Acad Radiol. 2010 Mar;17(3):291-7. doi: 10.1016/j.acra.2009.08.015. Epub 2009 Dec 4.
6
Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.生长抑素受体2免疫组织病理学表达与68Ga-DOTATOC PET/CT标准化摄取值的相关性
Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):48-52. doi: 10.1007/s00259-008-0944-5. Epub 2008 Sep 20.
7
Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study.生长抑素受体亚型在人体中的全身分布:一项免疫组织化学研究。
Endocr J. 2005 Oct;52(5):605-11. doi: 10.1507/endocrj.52.605.
8
An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.99mTc-EDDA/HYNIC-TOC与111In-DTPA-奥曲肽用于诊断生长抑素受体表达肿瘤的患者内比较
J Nucl Med. 2003 May;44(5):708-16.
9
99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives.99mTc-EDDA/HYNIC-TOC:一种用于成像生长抑素受体阳性肿瘤的新型99mTc标记放射性药物;首次临床结果及与111In标记奥曲肽衍生物的患者内比较
Eur J Nucl Med. 2000 Sep;27(9):1318-25. doi: 10.1007/s002590000289.
10
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.使用[111In-DTPA-D-Phe1] - 和[123I-Tyr3] - 奥曲肽的生长抑素受体闪烁扫描术:鹿特丹对1000多名患者的经验
Eur J Nucl Med. 1993 Aug;20(8):716-31. doi: 10.1007/BF00181765.